Biomimetic nano-surfactant stabilizes sub-50 nanometer phospholipid particles enabling high paclitaxel payload and deep tumor penetration. (October 2018)

• Record Type: Journal Article
• Authors: Choi, Hoon; Liu, Ting; Qiao, Hui; Chacko, Ann-Marie; Hu, Shang-Hsiu; Chen, San-Yuan; Zhou, Rong; Chen, I-Wei
• Is Part Of: Biomaterials. Volume 181(2018)
• Page Start: 240
• Page End: 251
• Publication Date: 2018-10
• Subjects: Nano medicine -- Drug delivery -- Phospholipid -- Liposomes -- Fluid-gel transition -- Surfactant -- Micelle -- Amphipathic peptides -- Lipoproteins -- Apolipoproteins -- Paclitaxel -- Breast cancer -- Her-2; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2018.07.034
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Sub-50 nm nanoparticles feature long circulation and deep tumor penetration. However, at high volume fractions needed for intravenous injection, safe, highly biocompatible phospholipids cannot form such nanoparticles due to the fluidity of phospholipid shells. Here we overcome this challenge using a nano-surfactant, a sterilized 18-amino-acid biomimetic of the amphipathic helical motif abundant in HDL-apolipoproteins. As it induces a nanoscale phase (glass) transition in the phospholipid monolayer, the peptide stabilizes 5–7 nm phospholipid micelles that do not fuse at high concentrations but aggregate into stable micellesomes exhibiting size-dependent penetration into tumors. In mice bearing human Her-2-positive breast cancer xenografts, high-payload paclitaxel encapsulated in 25 nm (diameter) micellesomes kills more cancer cells than paclitaxel in standard clinical formulation, as evidenced by the enhanced apparent diffusion coefficient of water determined by in vivo MR imaging. Importantly, the bio-inertness of this biomimetic nano-surfactant spares the nanoparticles from being absorbed by liver hepatocytes, making them more generally available for drug delivery.